Mar 17, 2019
MediSieve as a Finalist of the MedTech London Awards 2019
MediSieve is a finalist in the Investment category of this year’s MedTech London Awards.
The Investment category is highly competitive and we are one of two companies that has made it to the final.
Date: Tuesday 30th April 2019
Venue: Hill Dickinson, The Broadgate Tower, 20 Primrose Street, London EC2A 3EW
Times: 16:30 - 20:00
We’ll keep you posted on the outcome.
Wish us luck.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: